Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1982 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
 


 

 
     
    Advanced search
 

 
 
     
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    Introduction
    Efficacy of Anti...
    Research on Othe...
    Conclusion and F...
    References
    Article Tables

 Article Access Statistics
    Viewed3611    
    Printed112    
    Emailed2    
    PDF Downloaded526    
    Comments [Add]    

Recommend this journal

 


 
REVIEW ARTICLE Table of Contents   
Year : 2010  |  Volume : 52  |  Issue : 7  |  Page : 317-340
Research on antipsychotics in India


1 Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Pharmacology, Shadan Institute of Medical Sciences, Hyderabad, India

Click here for correspondence address and email

Date of Web Publication15-Sep-2010
 

   Abstract 

Antipsychotic as a class of medications became available for treatment of various psychiatric disorders in the early 1950's. Over the last 60 years many antipsychotics have become available. In line with the west, Indian researchers have evaluated the efficacy of antipsychotics in various conditions. Additionally, researchers have also evaluated the important safety and tolerability issues. Here, we review data originating from India in the form of drug trials, effectiveness, usefulness, safety and tolerability of antipsychotics. Additionally, data with respect to other important treatment related issues is discussed.

Keywords: Antipsychotic, research, India

How to cite this article:
Avasthi A, Aggarwal M, Grover S, Khan MR. Research on antipsychotics in India. Indian J Psychiatry 2010;52, Suppl S3:317-40

How to cite this URL:
Avasthi A, Aggarwal M, Grover S, Khan MR. Research on antipsychotics in India. Indian J Psychiatry [serial online] 2010 [cited 2019 Nov 18];52, Suppl S3:317-40. Available from: http://www.indianjpsychiatry.org/text.asp?2010/52/7/317/69261



   Introduction Top


When one looks at the history of psychiatric treatments, prior to availability of electroconvulsive therapy (ECT), measures like magic, restraints, blood letting, emetics, purgatives, surgical operations on various organs, removal of foci of infections, vaccines and endocrines were tried as treatment options for schizophrenia. Therapies like insulin coma and electroconvulsive therapy became available. [1] However, the era of pharmacotherapy for treatment of schizophrenia started with use of chlorpromazine by Delay and Deniker for the treatment of patients suffering from schizophrenia in early 1950's. Over the next half century, a large number of drugs have been evaluated and marketed as antipsychotics. This class of drugs also helped in understanding the neurobiology of schizophrenia to some extent. This class of drug has also changed the attitude of the clinicians towards the expected outcome of the disorder.

India, as a country was not isolated from all these developments. Over the years many classes of antipsychotics have become available in India, some of which have stood the test of time and are still in use and some are no more marketed or are no more favorite of the clinicians. Research focusing on the usefulness of psychotics in India has more or less followed the trends in the West; however, some of the newer antipsychotic drugs which are currently marketed have not been evaluated as thoroughly as others. The pharmaceutical industry and the policy of the government have ensured that these medications are available at a reasonable price.

This review focuses on research done on various anti psychotics in India. For this a thorough internet search was done using key words like India, antipsychotics, name of each antipsychotic, efficacy, effectiveness, usefulness, tolerability, side effects, metabolic syndrome, weight gain, prescription, cost in various combinations. Various search engines like PUBMED, GOOGLE SCHOLAR, SCIENCEDIRECT, SEARCH MEDICA, SCOPUS, and MEDKNOW were used. In addition, a through search of all the issues of Indian Journal of Psychiatry available online was done. Hand search of some of the missing issues was also attempted and this yielded a few more articles. We have excluded review articles which we felt did not reflect the Indian scenario to a large extent or did not cover the available Indian data. Data from the animal studies that originated in the form of case reports and studies published only as abstract have not been included.


   Efficacy of Antipsychotics in Schizophrenia Top


Efficacy of first generation antipsychotics in schizophrenia [Table 1]
Table 1: Efficacy of first generation antipsychotics in schizophrenia

Click here to view


Twenty eight studies which have evaluated the efficacy of first generation oral antipsychotics in schizophrenia have been published. [2],[3],[4],[5],[6],[7],[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25],[26],[27],[28],[29] Of these, most have been open trials, some have been double blind randomized controlled trials and only a few have compared active drug with placebo. Some have also followed the cross over design with intermediate drug free period. Some of the initial trials included subjects who had not responded to previous pharmacological or somatic treatment and were suffering from chronic schizophrenia. Further, some studies have included treatment refractory subjects and others have recruited only those subjects who responded to some medication in the past. The sample size has varied from 15 to 145 subjects and the duration of trials have varied from eight days to six months, but most have evaluated the subjects in 4-12 weeks. Most of the trials included subjects with acute symptoms, however, one trial evaluated the efficacy of penfluridol and haloperidol in the maintenance phase and another included subjects who, on baseline, had shown at least 50% response on BPRS to the previous antipsychotic medication. [29]

Except for some of the trials in the 1960s and early 1970s, the efficacy and side effects were measured on some rating scales. All these trials have not used the dropouts in their final analysis of data. Data from all these trials can be summarized as: Typical antipsychotics are useful for treatment of schizophrenia, typical antipsychotics are more efficacious than placebo in the treatment of schizophrenia, improvement is seen more in paranoid and catatonic symptoms, aggression and less so in depressive symptoms; addition of trihexyphenidyl doesn't reduce the efficacy of antipsychotic like trifluperazine and extrapyramidal symptoms are common with typical antipsychotics.

Efficacy of injectable depot first generation antipsychotics in schizophrenia [Table 2]
Table 2: Efficacy studies of injectable depot antipsychotics in schizophrenia/psychosis

Click here to view


Nine trials have evaluated the efficacy of depot antipsychotics in schizophrenia. [30],[31],[32],[33],[34],[35],[36],[37],[38] Some of these trials have just focused on short term outcome (2-4 weeks), whereas others have evaluated the outcome after six months. One trial followed up the subjects for 1-3 years. [37] In most of these trials subjects included were those who were non-complaint to oral medications and had frequent relapse. All these were open label and did not use a comparator group, except for the trial by Bagadia et al.[36] that compared subjects on fluphenazine decanoate with subjects who has been receiving either chlorpromazine or trifluperazine. All these studies have shown that depot antipsychotics are useful in the management of schizophrenia in acute phases and also for maintenance treatment.

Efficacy studies of first generation antipsychotics vs. electroconvulsive therapy/electroconvulsive therapy and first generation antipsychotics in schizophrenia [Table 3]
Table 3: Comparative efficacy studies of first generation antipsychotics vs. electroconvulsive therapy/electroconvulsive therapy and first generation antipsychotic in schizophrenia

Click here to view


Thirteen studies have compared typical antipsychotics with either electroconvulsive therapy (ECT) alone or a combination of ECT and typical antipsychotic medication. [1],[39],[40],[41],[42],[43],[44],[45],[46],[47],[48],[49],[50] All studies have specified the diagnosis as schizophrenia, except for one study, in which the diagnosis was mentioned as functional psychosis. [45] A common theme which emerges from these studies is that typical antipsychotic, alone or when used in combination with ECT, produces similar response rate in short term, but addition of ECT leads to a faster response. The only study which evaluated the efficacy of ECT and chlorpromazine in treatment resistant schizophrenia (TRS) showed that augmentation with ECT in TRS may be a worthwhile option. [50]

Efficacy of centbutindole [Table 4]
Table 4: Efficacy studies of centbutindole in schizophrenia

Click here to view


Centbutindole was developed by Central Drug Research Institute, Lucknow; it has been evaluated in four trials and has been compared with trifluperazine, haloperidol and risperidone (see [Table 5] for this trial). [51],[52],[53],[54] These studies have shown that centbutindole is as efficacious as haloperidol, trifluperazine and risperidone in the treatment of schizophrenia.
Table 5: Efficacy studies of second generation antipsychotics in schizophrenia

Click here to view


Efficacy studies of second generation antipsychotics in schizophrenia [Table 5]

Twenty studies have been published on evaluation of the efficacy/effectiveness of second generation antipsychotics in schizophrenia. [54],[55],[56],[57],[58],[59],[60],[61],[62],[63],[64],[65],[66],[67],[68],[69],[70],[71],[72],[73] Of these trials, 11 have reported the efficacy of risperidone, five of clozapine, two of olanzapine, two of aripiprazole and one of quetiapine. Some of these studies have also evaluated different doses of the same medications and some others have evaluated the dosing schedule. All these trials have included subjects diagnosed as schizophrenia on the basis of DSM-IV or ICD-10 except for Agashe et al.[58] who used DSM-IIIR criteria. All these trials have used standard instruments to assess the efficacy and side effects. The sample size has varied from 30 to 606 and the duration of these trials have been six weeks to four months except for one trial which evaluated the outcome on risperidone at one year [61] and two studies, which followed up subjects on clozapine for 20 months and three years respectively. [66],[69] All the studies on risperidone have shown that it is efficacious in short term. Studies which have compared risperidone with other antipsychotic have shown it to be more efficacious than quetiapine but as efficacious as haloperidol and centbutindole. Agarwal and Chadda [64] demonstrated that there was no difference in efficacy of once daily dose versus twice daily dose of risperidone. The study which followed up the subjects on risperidone for one year showed that compared to haloperidol, more subjects on risperidone had better social functioning, productivity and education and significantly fewer patients had suicidal ideation or attempts and needed rehospitalization. [61] Srivastava et al.[62] showed that half of the schizophrenia subjects in India require 3-4 mg/day of risperidone and another one-third improve with dose ranging from 1-2 mg/ day. All the studies which have evaluated clozapine have done so in TRS cases and have reported it to be useful in both short and long term. In the study by Avasthi et al.[65] olanzapine was found to be as efficacious as haloperidol on PANSS. Additionally olanzapine was found to be better than haloperidol in reducing associated depressive and anxiety symptoms. Sarin et al.[68] reported no difference in efficacy of 10 and 15 mg/day of aripiprazole.

Efficacy of antipsychotics in other disorders: mania [Table 6]
Table 6: Efficacy studies of antipsychotics in mania

Click here to view


Some of the older studies included a few subjects with mania. Three studies in the early 60s included very few subjects in the open label design studies and reported efficacy of haloperidol, thioridazine and thioproperazine in the treatment of mania. [4],[6],[8] One study included only one case of treatment refractory mania and showed that oral fluphenazine was not useful in such subjects. [5] Another study evaluated the efficacy of zuclopenthixol in management of 25 cases of mania. This study did not specifically report the efficacy of zuclopenthixol in mania, but irrespective of the diagnosis the reported outcome suggests that zuclopenthixol for eight weeks was useful. [74]

However, in the recent trials, atypical antipsychotics have been evaluated in large samples in double blind placebo control trials and the outcomes have been measured using standard instruments. In the study by Khanna et al. [75] risperidone was found to be significantly better than placebo at weeks 1 and 2 and 3 (total YMRS: P < 0.01). Another multicentric trial, which included subjects from India too, showed that both risperidone and haloperidol were better than placebo; however, there was no difference in the efficacy of risperidone and haloperidol. [76] At three weeks, more patients were treatment responders (>50% reduction in YMRS total scores) among those treated with risperidone (48%) or haloperidol (47%) than placebo (33%). The difference between risperidone and placebo was significant ( P < 0.01). At 12 weeks, the response rate was maintained in almost all subjects who responded at three weeks and additionally more than 80% of the subjects who did not respond (reduction of >50% in the YMRS total score) to risperidone or haloperidol at three weeks but continued the medications responded at 12 weeks.

Acute psychosis [Table 7]
Table 7: Efficacy studies of antipsychotic in acute psychosis

Click here to view


Four studies have reported the efficacy of antipsychotics in the management of acute psychosis, of which three have specified that the trials included subjects with acute and transient psychosis, [60],[74],[77] while another trial mentioned the diagnostic category only as acute psychosis. [78] Trial by Agarwal and Sitholey [77] involved children and adolescents presenting with acute and transient psychosis and is discussed later. These studies suggest that thioproperazine is better than chlorpromazine and there is no difference in short term efficacy of risperidone and haloperidol in acute and transient psychosis. As mentioned earlier Fernandes et al. [74] did not specifically report the outcome in acute and transient psychosis, however, irrespective of the diagnosis the reported outcome suggests that zuclopenthixol for eight weeks was useful.

Anxiety

Studies in 1970s and 1980s evaluated the efficacy of low dose haloperidol, [79] flupenthixol, [80] trifluperidol, [81] pimozide, [82] prochlorperazine, [83] trifluperazine [84] in various anxiety states and reported these to be efficacious. The study which used pimozide compared it with chlordiazepoxide and reported it to be useful, but inferior to chlordiazepoxide. [82] The study which compared trifluperazine and chlordiazepoxide combination with prochlorperazine reported the latter to be better. [83]

Agitation and violence

Two studies have evaluated the role of antipsychotic in violent and agitated subjects attending the psychiatry emergency settings. In a randomized controlled trial, Alexander et al. [84] compared the efficacy of injectable lorazepam and a combination of injectable haloperidol and promethazine and reported that after four hours of the injection, 96% of the subjects in both the groups were tranquil or asleep. However, in terms of being asleep, 76% of the subjects given haloperidol-promethazine were asleep compared to 45% of subjects in the lorazepam group. The haloperidol-promethazine combination also produced a faster onset of tranquillization/sedation and more clinical improvement over the first 2 h. Neither intervention differed significantly in the need for additional intervention or physical restraints, subjects absconding, or adverse effects. In another randomized study from the same centre, Raveendran et al. [85] compared the efficacy of intramuscular olanzapine with intramuscular haloperidol plus promethazine in 300 subjects and reported that both treatments led to similar proportions of subjects being tranquilized or asleep at 15 minutes (olanzapine-87%, haloperidol plus promethazine-91%) and 240 minutes (olanzapine-96% and haloperidol plus promethazine-97%). However, compared to those given haloperidol plus promethazine, more subjects in the olanzapine group required additional drugs over four hours (21% vs. 43%). Adverse effects were uncommon with both treatments.

Delirium

Only a small case series of seven cases reported that risperidone is effective in the management of delirium and it is well tolerated by these subjects. [86]

Delusional disorders

Good response to antipsychotics like trifluperazine, haloperidol and chlorpromazine was reported in cases of delusional parasitosis. [87] In their study on delusional disorder, Grover et al.[88] found that best response was seen with risperidone, followed closely by pimozide. Of the 20 subjects treated with risperidone, six were considered to have good response (>75% reduction in symptoms) and nine were considered to have partial response (>25 but <75% reduction in symptoms). Of the 18 subjects treated with pimozide, four qualified for good response and six as partial responders.

Use of Antipsychotic in Children and Adolescents [Table 8]
Table 8: Efficacy studies of antipsychotic in children and adolescents

Click here to view


Seven studies have evaluated the efficacy of various antipsychotics in childhood disorders or childhood/adolescent onset disorders. Studies done in 1960s and early 70s evaluated the role of antipsychotics primarily in the behavioral problems in children with epilepsy/epilepsy and mental retardation and have shown that trifluperazine, prothipendyl and trifluperidol are useful but fluphenazine is ineffective. One small study evaluated the usefulness of clozapine in childhood onset schizophrenia. [91] A study which evaluated the role of risperidone in autism showed promising results [92] and another study demonstrated the efficacy of olanzapine in childhood/adolescent onset acute and transient psychosis. [77] However, the studies which used olanzapine and risperidone showed that these drugs lead to reasonable weight gain, which may be cause of concern.


   Research on Other Treatment Related Issues Top


Pharmacogenomics

With increasing interest in the role of genetic factors in treatment response and side effects of medications, studies from India have tried to address the genetic links of tardive dyskinesia, treatment response and severity of psychopathology. [93],[94],[95],[96] However, the findings are preliminary and inconclusive. Tiwari et al.[93] evaluated the role of six single nucleotide polymorphisms (SNP) in tardive dyskinesia and showed that CYP1A2 1545 C > T SNP was associated with TD ( P= 0 .03) and schizophrenia ( P = 0 .04), but the association was rendered insignificant after corrections for multiple comparisons. Vijayan et al.(2007) [94] studied various alleles, genotypes, haplotypes and their linkage disequilibrium and observed that H313HTT genotype was associated with schizophrenia and TaqIB1B1 genotype was significantly associated with higher psychopathology score. Subjects with H313HCC, TaqIA2A2 and Taq1D1D1 had higher mean improvement scores. Distinct shift in the linkage disequilibrium pattern of responder and non responder group was observed. Thomas et al.[95] reported that average olanzapine dose, baseline weight and dopamine receptor D-4 (DRD4-120 bp) duplication marker have significant association with the efficacy index. Gupta et al.[96] reported significant allelic associations of two SNPs (rs4633 and rs4680) with drug response.

Predictors of Treatment Response

A study reported that subjects, who showed initial dysphoric response to a test dose of neuroleptic, later respond poorly to the neuroleptics. [97]

Prescription Patterns

A few studies have evaluated the antipsychotic prescription patterns from India. In one of the early studies, Khanna et al. [98] evaluated the psychotropics drug prescription pattern in chronic long stay patients at Ranchi and compared the prescription trends in 1984 and 1988. Most of the patients whose prescriptions were reviewed were suffering from schizophrenia. More than one antipsychotic medication was prescribed to 13% in 1984, which fell down to 7% in 1988. Further it was seen that very few patients received anticholinergic agents and the use of benzodiazepines increased over the years (4% in 1984 and 10% in 1988), which authors attributed to development of distressing tardive dyskinesias over the years. In an evaluation of prescriptions at discharge of patients with schizophrenia, Padmini Devi et al.[99] reported that risperidone was the most commonly prescribed antipsychotic (56.17%), followed by olanzapine (21.34%) and quetiapine (3.93%). Typical antipsychotics were used only in 15.73% of cases and polypharmacy (concurrent use of more than 1 antipsychotic) was seen in 9% of cases. In another study from Jammu, Shanwey et al.[100] evaluated the prescription of 270 outpatients, and reported that fixed dose formulation of trifluperazine, chlorpromazine and trihexyphenidyl (parkinforte) was used in 45.4% of cases followed by chlorpromazine[36.3%] and quetiapine [34.5%]. The authors also found that typical antipsychotics were used in 82.72% of cases and polypharmacy was seen in 72.72% of cases. Dutta et al.[101] evaluated the prescription patterns in 118 stable schizophrenia subjects and reported that on an average 2.8 medications were prescribed to each subject and olanzapine was the most commonly prescribed antipsychotic followed by haloperidol and risperidone. About half of the subjects were receiving more than one antipsychotic. All these findings suggest that antipsychotic prescriptions vary from centre to centre and possibly have changed over the years.

In a recently conducted survey, Grover and Avasthi [102] found that the three most commonly prescribed antipsychotics by Indian psychiatrists were risperidone, olanzapine and haloperidol. Typical antipsychotics comprise 25.15% of all prescriptions and in about 22.36% of cases the psychiatrists were using more than one antipsychotic in the same patient. Another survey specifically assessed the prescribing practices of clozapine; only 28% of psychiatrists reported that their prescription of clozapine was guided by their knowledge about the efficacy of clozapine. Majority of the psychiatrists opined that clozapine leads to symptom reduction to the extent of 40 to 70%, and the average dose required for stabilization was between 75 to 300 mg/day. Only 16% of psychiatrists preferred to combine clozapine with other antipsychotics. In terms of blood monitoring, 80% of the psychiatrists monitored the blood counts weekly in the first month of therapy and then once monthly for next 6 months and further monitoring was done as per the need. [103]

Treatment continuation, compliance and attitude towards treatment

Khanna et al.[104] reported that 31% of the subjects with schizophrenia do not keep their appointment for detail evaluation after initial evaluation in the walk-in clinic. The authors also reported that 32% of the subjects stop attending the clinic after initial detailed workup and diagnostic clarification. In another study from the same center, Kulhara et al.[105] reported that 25% of schizophrenia subjects do not come for follow-up after six months of detailed workup and diagnostic clarification and 23% of subjects with schizophrenia don't seek any medical help in next five years. Murthy et al.[106] studied a mixed group of patients (which included subjects of psychosis also) and reported that duration of illness more than six months, residence at a distance of more than 50 kilometers from the hospital and psychiatric diagnosis other than functional psychosis favored treatment discontinuation. Ponnudurai et al.[107] evaluated the treatment adherence in 111 cases of psychotic illness (mostly schizophrenia) by Ferric Chloride reagent test to look for excretion of phenothiazine in urine and reported non-adherence in 19% of subjects. In another interesting study Srinivasan and Thara [108] reported that history of noncompliance with oral medication was seen in about 58% of patients during the course of their illness and half of these subjects were given oral medications at least once without their knowledge by the family members under the psychiatrist's advice. It was seen that spurious administration of antipsychotic leads to reduction in symptoms in 91% of subjects given medications in this way and helps to convince the patient to take oral medications subsequently. Half of the caregivers who participated in the study felt that spurious administration of antipsychotic was the right action under the circumstances. In a recent study, Baby et al.[109] reported rates of non-compliance with medication to be 38.7% in subjects with schizophrenia. The authors also reported that a majority of the patients and family members had a positive attitude towards medication and treatment. Further, family members are able to identify the compliance status of the patients and the reasons for the noncompliance better than the patients. The factors which had significant influence on the medication compliance included perceived daily benefit from medication, positive relationship with the psychiatrist, pressure from the family and health system and positive family belief towards illness and treatment. The significant reasons for noncompliance are no perceived daily benefit from medications, difficulty in gaining access to treatment and medications, financial obstacles, embarrassment or stigma related to treatment and medications and medicines currently not perceived as necessary. Besides attitude, other factors which are significantly associated with noncompliance include lower educational status, rural area of stay, adjustment difficulty with family and spouse, previous history of non-compliance, poor insight into illness, higher positive PANSS score. Past history of hospitalization was associated with better compliance with medications.

Impact of antipsychotics on disability

A recently published study, which compared three groups of community dwelling subjects with schizophrenia, showed that mean disability scores remain virtually unchanged in those who remained untreated, but showed a significant decline (indicating decrement in disability) in those who continued to receive antipsychotics and in those in whom antipsychotic treatment was initiated. The proportion of patients classified as 'disabled' declined significantly in the treated group, but remained the same in the untreated group. [110]

Costs

A few studies have evaluated the cost of antipsychotics per se and cost of management of schizophrenia. Girish et al.[111] found that antipsychotic drugs are affordable and comparable to drug treatment costs of other physical illnesses. They found the monthly cost of treatment with chlorpromazine was Rs.55, an equivalent dose of trifluperazine amounted to Rs.25/month, risperidone Rs.60 and clozapine Rs.225 per month. They also concluded that although antipsychotic drugs are affordable, the other costs associated with treatment make them more expensive, like co-prescribed antiparkinsonian agents, antidepressants, anxiolytics etc. Sarma [112] showed that cost of one outpatient visit was Rs.201 in which medications accounted for less than 10% of the total cost. Grover et al.[113] found that the total annual cost of care of schizophrenia amounted to Rs.13687.38, which was similar to cost of treatment of diabetes mellitus. Money spent by patients on buying drugs constituted about 18% of the total costs. A study from Chennai showed that despite the cost of blood tests, the total cost of treatment with clozapine came down by nearly 25% compared to the cost before clozapine was started. [114] In another study, Despande [115] reported that the cost of medication to the hospital which provided free medications to subjects with schizophrenia was Rs.288-less than the cost of medications for bipolar disorders.

Research on Tolerability and Side Effects of Antipsychotic [Table 9]
Table 9: Side effects of antipsychotics

Click here to view


Besides the efficacy or usefulness studies, some studies have specifically evaluated the side effects and tolerability issues with antipsychotics. [116],[117],[118],[119],[120],[121],[122],[123],[124],[125],[126],[127],[128],[129],[130],[131],[132],[133],[134],[135],[136] In one of the earliest studies, Sarada Menon and Ramachandran [116] reported side effects of subjects who participated in two of their drug trials and had received either trifluperazine or trifluperidol. Other studies have evaluated the rates of skin pigmentation with phenothiazines, [117] rise in prolactin levels with chlorpromazine and trifluperazine [119] and changes in serum electrolytes. [120] Studies have reported prevalence rate of akathesia (25-28%), tardive dyskinesia (5-25.5%) and dystonia (17%) in subjects receiving typical antipsychotic. [118],[121],[122],[123] Studies have also evaluated the incidence of neuroleptic malignant syndrome [124],[134] and extrapyramidal side effects with risperidone. [125] Another study by Pandey et al.[136] compared the rate of neuroleptic - induced acute dystonia and reported that there was no difference in vulnerability to develop dystonias in subjects with mania or schizophrenia. With recent interest in weight gain and metabolic syndrome, some of the studies have shown that patients receiving atypical antipsychotics (Olanzapine or risperidone) gain more weight compared to haloperidol and treatment with antipsychotic leads to disturbance in metabolic syndrome parameters [131],[132],[133] whereas others suggest contrary findings. [129],[130] Studies have also shown that use of typical antipsychotic leads to higher rates of sexual dysfunction [128] and among the atypical antipsychotic sexual desire is more frequently impaired in subjects on risperidone and erectile dysfunction is more prevalent in subjects on olanzapine. [135]


   Conclusion and Future Directions Top


Reasonably good amount of data on the efficacy of antipsychotics in schizophrenia is available from India. In addition, studies also suggest usefulness of antipsychotics in mania, acute and transient psychosis, delusional disorders and agitation and violence. Older studies also suggest that typical antipsychotics have usefulness in anxiety states. Many of the recent studies followed double blind randomized controlled design and had a reasonable sample size. Further, many studies have been carried out at multiple sites throughout the country. To some extent, data is also available with regards to the tolerability of antipsychotics and it shows that extrapyramidal symptoms and NMS are more common with typical antipsychotics and weight gain is more common with antipsychotics like olanzapine and risperidone.

However, the major limitation of the research is that there are not many studies on the treatment of schizophrenia in elderly, in subjects with comorbid physical illnesses and in cases with comorbid substance abuse. Data on long term efficacy of antipsychotics is also meager. There is still a need to conduct long term comparative multicentric studies to evaluate the efficacy, effectiveness, tolerability and side effects of antipsychotics.

 
   References Top

1.Bagadia VN, Dave KP, Shah LP. A comparative study of physical treatments in schizophrenia. Indian J Psychiatry 1970;12:190-204.  Back to cited text no. 1    Medknow Journal  
2.Doongaji, DR, Bagadia VN, Vahia NS. Clinical experience with prothipendyl hydrochloride (dominal) -a new tranquiliser. Indian J Psychiatry 1961;3:228-34.  Back to cited text no. 2      
3.Sarada Menon M. Prochlorperazine in the treatment of chronic withdrawn schizophrenia. Indian J Psychiatry 1961;3:157-9.  Back to cited text no. 3      
4.Damania GB, Masani KR. Clinical evaluation of Melleril-a new tranquilizer. Indian J Psychiatry 1961;3:95-9.  Back to cited text no. 4      
5.Kothari UC. Clinical experience with fluphenazine in psychotic patients. Indian J Psychiatry 1962;4:37-9.  Back to cited text no. 5    Medknow Journal  
6.Bhaskaran K. Clinical trials with Thioproperazine (Majeptil). Indian J Psychiatry 1964;6:123-30.  Back to cited text no. 6    Medknow Journal  
7.Thomas G, Narayanan HS. Trifluoperazine (eskazine) in the treatment of chronic paranoid schizophrenics-(a comparative study with unichlor promazine). Indian J Psychiatry 1965;6:175-80.  Back to cited text no. 7      
8.Jetley SK. Haloperidol - a clinical trial. Indian J Psychiatry 1966;8:251-4.  Back to cited text no. 8    Medknow Journal  
9.Dube K, Mathur RS. Clinical trial with melleril. Indian J Psychiatry 1966;8:277-90.  Back to cited text no. 9    Medknow Journal  
10.Narayan HS, Natarajan CL, Saroja Bai BK. Stemetil in chronic schizophrenia. Indian J Psychiatry 1967;9:234-8.  Back to cited text no. 10    Medknow Journal  
11.Teja JS. Thioproperazine: A trial in outpatient schizophrenics. Indian J Psychiatry 1967;9:61-72.  Back to cited text no. 11    Medknow Journal  
12.Sarada Menon SM, Haneef Badsha M. Clinical trial of thiothixine (in hospitalized chronic schiziophrenia patient in Government Mental Hospital, Madras. Indian J Psychiatry 1968;10:57-63.  Back to cited text no. 12      
13.Kishore B, Kumar R, Kaur A. Thiothixene in hospitalised chronic schizophrenic patients. Indian J Psychiatry 1970;12:225-37.  Back to cited text no. 13    Medknow Journal  
14.Bagadia VN, Doshi S, Hebbar YV Chawla R, Saraf KR, Shah LP, et al. Flupenthixol in schizophrenia. Indian J Psychiatry 1972;14:24-30.  Back to cited text no. 14    Medknow Journal  
15.Bagadia VN, Jeste DV, Chawla R, Shah LP, Saraf KR. Trifluoperidol in schizophrenia. Indian J Psychiatry 1972;14:31-7.  Back to cited text no. 15    Medknow Journal  
16.Ramchandran V, Sarda Menon M. Trifluperidol-a controlled clinical trial on a group of schizophrenia patients. Indian J Psychiatry 1972;14:11-8.  Back to cited text no. 16      
17.Vyas BK, Bapna G. Phase I clinical study of GO 3315 in acute schizophrenics, Indian J Psychiatry 1972;14:39-44.  Back to cited text no. 17      
18.Kishore B, Jam KC, Bhatia AS. Trifluperidol: A butyprophenone in hospitalized chronic schizophrenia patients (a comparative study with thiothixine and prochlorperazine). Indian J Psychiatry 1972;14:65-75.  Back to cited text no. 18    Medknow Journal  
19.Kishore B, Dhillon AK. Clinical efficacy of pimozide in hospitalized chronic schizophrenics. Indian J Psychiatry 1973;15:311-8.  Back to cited text no. 19      
20.Sarada Menon M, Ramachandran V, Kakaturriangan V. A controlled trial of pimozide (R 6238): A new neuroleptic. Indian J Psychiatry 1973;15:325-8.  Back to cited text no. 20      
21.Bagadia VN, Chandiali HN, Pradhan PU, Shah LP. Pimozide (R 8238) in schizophrenia-a pilot study. Indian J Psychiatry 1973;15:319-24.  Back to cited text no. 21    Medknow Journal  
22.DeSousa A, Nayani GR. A controlled trial of trifluperidol with trifluoperazine. Indian J Psychiatry 1973;15:290-3.  Back to cited text no. 22      
23.Mahal AS, Janakiramiah N. A double-blind placebo controlled trial of pimozide (R6238) in 49 hospitalised chronic schizophrenics. Indian J Psychiatry 1975;17:45-55.  Back to cited text no. 23    Medknow Journal  
24.Channabasavanna SM, Kaliaperumal VG, Embar P, Shariff IA. Clinical trial of trifluoperidol: Our experience. Indian J Psychiatry 1976;18:193-8.  Back to cited text no. 24    Medknow Journal  
25.Sharma S, Dutta D. A double-blind study of pimozide in the treatment of schizophrenic patients. Indian J Psychiatry 1976;18:34-7.  Back to cited text no. 25    Medknow Journal  
26.Bagadia VN, Bhat R, Ghandiali HH, Pradhan PU, Shah LP. A comparative double blind trial of pimozide and trifluperazine in maintenance treatment of schizophrenia. Indian J Psychiatry 1976;18:199-203.  Back to cited text no. 26    Medknow Journal  
27.Dube S, Sethi BB. Efficacy of lithium in schizophrenia. Indian J Psychiatry 1981;23:193-9.  Back to cited text no. 27    Medknow Journal  
28.Sethi BB, Bhirnan A. A clinical study of trifluperazine vs. trifluperazine-benzhexol combination. Indian J Psychiatry 1983;25:155-6.  Back to cited text no. 28    Medknow Journal  
29.Channabasavanna SM, Michael A. Penfluridol maintenance therapy in schizophrenia: A controlled study. Indian J Psychiatry 1987;29:333-6.  Back to cited text no. 29    Medknow Journal  
30.Iyer DS, Doongaji DR, Vahia NS. Preliminary clinical impressions with "Moditen". A depot tranquilizer. Indian J Psychiatry 1968;10:78-80.  Back to cited text no. 30    Medknow Journal  
31.Bagadia VN, Varaiya PG. Fluphenazine enanthate injections in schizo phrenia-a clinical trial in 50 cases. Indian J Psychiatry 1971;13:119-30.  Back to cited text no. 31    Medknow Journal  
32.Bagadia VN, Shastri PS, Sule SM, Shah LP. Further experience with fluphenazine enathate injection. Indian J Psychiatry 1972;14:279-86.  Back to cited text no. 32    Medknow Journal  
33.Jha BK, Bhaskaran K. Experience with fluphenazine enanthate in long stay hospitalized schizophrenia. Indian J Psychiatry 1972;14:263-78.  Back to cited text no. 33    Medknow Journal  
34.Gehlot PS, Purohit DR, Garg AR, Mundhra RS. Experience with fluphenazine decanoate in chronic schizophrenia. Indian J Psychiatry 1977;19:74-8.  Back to cited text no. 34    Medknow Journal  
35.Bagadia VN, Bhatt R, Pradhan PV, Shah LP. Piportil injection (19552RP)- a depot neuroleptic in schizophrenia. Indian J Psychiatry 1979;21:259-61.  Back to cited text no. 35    Medknow Journal  
36.Bagadia VN, Abhaynbar RR, Gopalini JH, Jagadish R, Pradhan PV, Shah LP. Maintenance therapy of schizophrenia. Indian J Psychiatry 1979;21:106-8.  Back to cited text no. 36    Medknow Journal  
37.Shukla GD. Fluphenazine decanoate in chronic schizophrenia. Indian J Psychiatry 1981;23:234-6.  Back to cited text no. 37    Medknow Journal  
38.Varma VK, Kulhara P. Open drug trial with haloperidol decanoate injection in schizophrenia. Indian J Psychiatry 1989;31:144-50.  Back to cited text no. 38    Medknow Journal  
39.Ray SD. Relative efficacy of electroconvulsive therapy and chlorpromazine in schizophrenia. J Indian Med Assoc 1962;38:332-3.  Back to cited text no. 39      
40.Chatterjee AK, Bhusan V. Clinical trials with "Melleril" in psychiatric patients. Indian J Psychiatry 1963;5:140-6.  Back to cited text no. 40    Medknow Journal  
41.Dutta Ray S, Kapur RL. Significance of some prognostic indices of schizophrenics treated with ECT or chlorpromazine. Indian J Psychiatry 1963;5:190-5.  Back to cited text no. 41      
42.Janakiramaiah N, Subbakrishna DK. ECT-chlorpromazine combination compared with chlorpromazine only in schizophrenia. Indian J Psychiatry 1981;23:230-3.  Back to cited text no. 42    Medknow Journal  
43.Janakiramaiah N, Channabasavanna SM, Narshima Murthy NS. ECT/chlorpromazine combination versus chlorpromazine alone in acutely ill schizophrenic patients. Acta Psychiatr Scand 1982;66:464-70.  Back to cited text no. 43      
44.Natani GD, Gautam S, Gehlot PS. Comparison of three treatment regimes in schizophrenia. Indian J Psychiatry 1983;25:306-11.  Back to cited text no. 44    Medknow Journal  
45.Gangadhar BN, Choudhary JR, Channabasavanna SM. ECT and drug induced parkinsonism. Indian J Psychiatry 1983;25:212-3.  Back to cited text no. 45    Medknow Journal  
46.Bagadia VN, Abhyankar RR, Doshi J, Pradhan PV, Shah LP. A double blind controlled study of ECT vs. chlorpromazine in schizophrenia. J Assoc Physicians India 1983;31:637-40.  Back to cited text no. 46      
47.Agarwal AK, Winny GC. Role of ECT-phenothiazine combination in schizophrenia. Indian J Psychiatry 1985;27:233-6.  Back to cited text no. 47    Medknow Journal  
48.Abraham KR, Kulhara P. The efficacy o ECT in the treatment of schizophrenia. A comparative study. Br J Psychiatry 1987;151:152-5.  Back to cited text no. 48      
49.Sarkar P, Andrade C, Kapur B, Das P, Sivaramakrishna Y, Harihar C, et0 al. An exploratory evaluation of ECT in haloperidol-treated DSM IIIR schizophreniform disorder. Convuls Ther 1994;19:271-8.  Back to cited text no. 49      
50.Goswami U, Kumar U, Singh B. Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: A double-blind study. Indian J Psychiatry 2003;45:26-9.  Back to cited text no. 50    Medknow Journal  
51.Doongaji DR, Sheth AS, Paul T, Parikh RM, Vahora SA, Apte JS, et al. Clinical evaluation of centbutindole as an anti-psychotic agent. Indian J Med Res 1983;78:126-33.  Back to cited text no. 51      
52.Doongaji DR, Satoskar RS, Sheth AS, Apte JS, Desai AB, Shah BR. Centbutindole vs. trifluoperazine: A double-blind controlled clinical study in acute schizophrenia. J Postgrad Med 1989;35:3-8.  Back to cited text no. 52  [PUBMED]  Medknow Journal  
53.Singh H, Srivastava JS, Raghuvanshi C, Dalal PK, Asthana OP. A comparative efficacy study of centbutindole and haloperidol in schizophrenia. Indian J Psychiatry 1999;41:325-8.  Back to cited text no. 53    Medknow Journal  
54.Chandra R, Singh H, Dalal PK, Asthana OP, Srivastava JS. Comparative efficacy of centbutindole and risperidone in schizophrenia. Indian J Psychiatry 2002;44:365-71.  Back to cited text no. 54    Medknow Journal  
55.Agarwal AK, Sharma M, Srivastava S, Mullick M, Kumar A. An open clinical trial with clozapine in treatment resistant schizophrenics. Indian J Psychiatry 1997;39:70-5.  Back to cited text no. 55    Medknow Journal  
56.Agarwal AK, Bsahyam VSP, Channabasvanna SM, Dhavale HS, Khan MA, Khanna, S, et al. Risperidone in Indian patients with schizophrenia. Indian J Psychiatry 1998;40:247-53.  Back to cited text no. 56    Medknow Journal  
57.Bajaj P, Nihalani N, Shah N, Desai N, Shinde U, Raut N. Reemergence of positive symptoms of schizophrenia in course of treatment with risperidone. Indian J Psychiatry 1999;41:96-9.  Back to cited text no. 57    Medknow Journal  
58.Agashe M, Dhawale DM, Cozma G, Mogre V. Risperidone in schizophrenia. Indian J Psychiatry 1999;41:54-9.  Back to cited text no. 58    Medknow Journal  
59.Desai N, Jain V, Ghalsasi S, Delvi M, Kelkar S. An open study of clozapine in the treatment of resistant schizophrenia. Indian J Psychiatry 1999;41:336-40.  Back to cited text no. 59    Medknow Journal  
60.Chaudhuri BP, Bhagabati D, Medhi D. Risperidone versus haloperidol in acute and transient psychotic disorder. Indian J Psychiatry 2000;42:280-90.  Back to cited text no. 60    Medknow Journal  
61.Shrivastava A, Gopa S. Comparative study of risperidone and haloperidol on clinical and psychosocial parameters in treatment of schizophrenia: A randomised open trial. Indian J Psychiatry 2000;42:52-6.  Back to cited text no. 61    Medknow Journal  
62.Srivastava AK, Gupta S, Srinivasan N. Risperidone: Dosing pattern and efficacy in clinical practice- a post-marketing survey. Indian J Psychiatry 2001;43:147-51.  Back to cited text no. 62      
63.Suresh Kumar PN, Andrade C, Krishnakutty N, Muralidharan Nair S. An open clinical trial with risperidone in chronic schizophrenia. Indian J Psychiatry 2001;43:152-6.  Back to cited text no. 63      
64.Agarwal V, Chadda RK. Once daily dose in treatment of schizophrenia. Indian J Psychiatry 2001;43:32-5.  Back to cited text no. 64    Medknow Journal  
65.Avasthi A, Kulhara P, Kakkar N. Olanzapine in treatment of schizophrenia: An open label comparative clinical trial from India. Indian J Psychiatry 2001;43:257-63.  Back to cited text no. 65    Medknow Journal  
66.Srivastava S, Agarwal AK, Sharma M. A three-year naturalistic follow-up of patients receiving clozapine: Report from India. Int J Psychiatry Clin Pract 2002;6:167-71.  Back to cited text no. 66      
67.Chavda RK, Laxmi L, Nair BS, Gandewar K. Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia and Schizoaffective Disorders. Indian J Psychiatry 2004;46:150-5.  Back to cited text no. 67    Medknow Journal  
68.Sarin A, Nagpal J, Bohra NK, Jiloha RC, Rao GP, Sharma SK, et al. Open labeled, randomized, switch-over study of two fixed doses (10/15 mg) of aripiprazole: To evaluate its safety and efficacy in the treatment of Indian patients of schizophrenia. Indian J Psychiatry 2004;46:64-71.  Back to cited text no. 68    Medknow Journal  
69.Raguraman J, Vijay Sagar KJ, Chandrasekaran R. Effectiveness of clozapine in treatment-resistant schizophrenia. Indian J Psychiatry 2005;47:102-5.  Back to cited text no. 69  [PUBMED]  Medknow Journal  
70.Vijay Sagar KJ, Chandrashekar CR. A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia. Indian J Psychiatry 2005;47:30-2.  Back to cited text no. 70      
71.Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85:254-65.  Back to cited text no. 71      
72.Thomas P, Srivastava V, Singh A, Mathur P, Nimgaonkar VL, Lerer B, et al. Correlates of response to olanzapine in a north indian schizophrenia sample. Psychiatry Res 2008;161:275-83.  Back to cited text no. 72      
73.Dutt A, Grover S, Chakrabarti S, Kulhara P, Avasthi A, Basu D, et al. Effectiveness of Clozapine: A study from North India. Asian J Psychiatry (in press)  Back to cited text no. 73      
74.Fernandes J, Pradhan PV, Choudhury P, Chatterji S, Pereira J, Shah H, et al. An open trial of zuclopenthixol in management of acute psychoses: A multicentered study. Indian J Psychiatry 1999;41:242-8.  Back to cited text no. 74    Medknow Journal  
75.Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. Br J Psychiatry 2005;187:229-34.  Back to cited text no. 75      
76.Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005;15:75-84.  Back to cited text no. 76      
77.Agarwal V, Sitholey P. A preliminary open trial of olanzapine in pediatric acute and transient psychotic disorders. Indian J Psychiatry 2006;48:43-6.  Back to cited text no. 77  [PUBMED]  Medknow Journal  
78.Mokashi JM, Chandorkar BL. Thioproperazine (Majeptil) in acute psychotic excitement. Indian J Psychiatry 1967;9:181-5.  Back to cited text no. 78      
79.Jayaram SS, Ram PK. Methods of assesment in a trial of haloperidol in anxiety neurosis. Indian J Psychiatry 1971;13:131-5.  Back to cited text no. 79    Medknow Journal  
80.Bagadia VN, Kotwani PN, Dave KP, Saraf KR, Shah LP. Fluphenthixol in certain psychiatric illness (a clinical trial). Indian J Psychiatry 1972;14:19-23.  Back to cited text no. 80    Medknow Journal  
81.Bagadia VN, Dave KP, Shah, LP. Further experience with trifluperidol- A study of 206 patients. Indian J Psychiatry 1972;14:45-54.  Back to cited text no. 81    Medknow Journal  
82.Ramachandran V, Sarada Menon M. A clinical trial of pimozide (R6238) in anxiety state. Indian J Psychiatry 1977;19:79-82.  Back to cited text no. 82    Medknow Journal  
83.Nigam P, Rastogi CK, Kapoor KK, Gupta AK. Prochlorperazine in anxiety. Indian J Psychiatry 1985;27:227-32.  Back to cited text no. 83    Medknow Journal  
84.Alexander J, Tharyan P, Adams CE, John T, Mol C, Philip J. Rapid tranquilisation of violent or agitated patients in a psychiatric emergency setting: A pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine. Br J Psychiatry 2004;185:63-9.  Back to cited text no. 84      
85.Raveendran NS, Tharyan P, Alexander J, Adams CE; TREC-India II Collaborative Group. Rapid tranquillization in psychiatric emergency settings in India: Pragmatic randomized controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 2007;335:865.  Back to cited text no. 85      
86.Gupta N, Sharma P, Mattoo SK. Effectiveness of Risperidone in Delirium. Can J Psychiatry 2005;50:75.  Back to cited text no. 86      
87.Srinivasan TN, Suresh TR, Jayaram V, Fernandez MP. Nature and treatment of delusional parasitosis: A different experience in India. Int J Dermatol 1994;33:851-5.  Back to cited text no. 87      
88.Grover S, Biswas P, Avasthi A. Delusional disorder: Study from north India. Psychiatry Clin Neurosci 2007;61:462-70.  Back to cited text no. 88      
89.Bassa OM. Some preliminary observation on the use of trifluperazine (Eskazine) on children. Indian J Psychiatry 1961;3:243-50.  Back to cited text no. 89    Medknow Journal  
90.Somasundaram O. Fluphenazine-a controlled trial in the management of chronic epileptics. Indian J Psychiatry 1967;9:213-25.  Back to cited text no. 90    Medknow Journal  
91.Malhotra S, Gupta N, Singh G. Clozapine in childhood-onset schizophrenia: A report of five cases. Clinical Child Psychology and Psychiatry 2000;5:403-10.  Back to cited text no. 91      
92.Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. J Child Neurol 2006;21:450-5.  Back to cited text no. 92      
93.Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, et al. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmaco genomics J 2005;5:60-9.  Back to cited text no. 93      
94.Vijayan NN, Bhaskaran S, Koshy LV, Natarajan C, Srinivas L, Nair CM, et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav Brain Funct 2007;3:34-45.  Back to cited text no. 94      
95.Thomas P, Srivastava V, Singh A, Mathur P, Nimgaonkar VL, Lerer B, et al. Correlates of response to olanzapine in a north indian schizophrenia sample. Psychiatry Res 2008;161:275-83.  Back to cited text no. 95      
96.Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmaco genomics 2009;10:385-97.  Back to cited text no. 96      
97.Borde M, Davis EJB, Sharma LN. Prediction of outcome in schizophrenia using the subjective response to a test dose of a neuroleptic. Indian J Psychiatry 1991;33:58-61.  Back to cited text no. 97      
98.Khanna R, Bhandari SN, Das A. Survey of psychotropic drug prescribing patterns for long stay patients. Indian J Psychiatry 1990;32:162-5.  Back to cited text no. 98    Medknow Journal  
99.Padmini Devi D, Amarjeeth R, Sushma M, Guido S. Prescription patterns of psychotropic drugs in hospitalized schizophrenic patients in a tertiary care hospital. Calicut Med J 2007;5:43.  Back to cited text no. 99      
100.Shanwey V, Chopra V, Kapoor B, Thappa JR, Tandon VR. Prescription trends in schizophrenia and manic depressive psychosis. J K Science 2005;7:156-8.  Back to cited text no. 100      
101.Dutta SB, Dhasmana DC, Bhardwaj R. Psychotropic drug utilization pattern among patients with schizophrenia. Indian J Psychiatry 2005;47:243-4.  Back to cited text no. 101  [PUBMED]  Medknow Journal  
102.Grover S, Avasthi A. Antipsychotic prescription pattern: A preliminary survey of psychiatrists in india. Indian J Psychiatry (in press)  Back to cited text no. 102      
103.Shrivastava A, Shah N. Prescribing practices of clozapine in India: Results of a opinion survey of psychiatrists. Indian J Psychiatry 2009;51:225-6.  Back to cited text no. 103  [PUBMED]  Medknow Journal  
104.Khanna BC. Treatment acceptance from walk-in clinic. Pilot study (unpublished data).  Back to cited text no. 104      
105.Kulhara PN. Long term follow-up study of schizophrenia. MD thesis 1974. PGIMER, Chandigarh.  Back to cited text no. 105      
106.Murthy SR, Ghosh A, Wig NN. Treatment Acceptance Patterns In A Psychiatric Out-Patient Clinic: Study Of Demographic And Clinical Variables. Indian J Psychiatry 1974;16:323-9.  Back to cited text no. 106    Medknow Journal  
107.Ponnudurai R, Vijayasekaran V, Kameswaran L, SomasundaramO, Rajendran AJ. Therapeutic compliance of patients on phenothiazines. Indian J Psychiatry 1983;25:239-42.  Back to cited text no. 107    Medknow Journal  
108.Srinivasan TN, Thara R. At issue: Management of medication noncompliance in schizophrenia by families in india. Schizophr Bull 2002;28:531-5.  Back to cited text no. 108      
109.Baby RS, Gupta S, Sagar R. Attitudes and subjective reasons of medication compliance and noncompliance among outpatients with schizophrenia in India. Internet J Epidemiol 2009;7.  Back to cited text no. 109      
110.Thirthalli J, Venkatesh BK, Kishorekumar KV, Arunachala U, Venkatasubramanian G, Subbakrishna DK, et al. Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia patients. Acta Psychiatr Scand 2009;119:209-17.  Back to cited text no. 110      
111.Girish K, Pratima M, Issac MK. Drug treatment in schizophrenia: Issues of comparability and costs. Indian J Psychiatry 1991;41:100-3.  Back to cited text no. 111      
112.Sarma PG. General hospital psychiatry: Cost of one visit. Indian J Psychiatry 2000;42:258-61.  Back to cited text no. 112    Medknow Journal  
113.Grover S, Avasthi A, Chakrabarti S, Bhansali A, Kulhara P. Cost of care of schizophrenia: A study of Indian out-patient attenders. Acta Psychiatr Scand 2005;112:54-63.  Back to cited text no. 113      
114.Thara R. Cost of illness of schizophrenia-perspective from an NGO. Indian J Psychiatry 2005;47:205-17.  Back to cited text no. 114      
115.Desphande SN. Perspective from a general hospital psychiatric unit. Indian J Psychiatry 2005;47:210-2.  Back to cited text no. 115      
116.Sarada Menon M, Rarnachandra V. Trifluperidol therapeutic response and extra pyramidal symptoms. Indian J Psychiatry 1972;14:289-92.  Back to cited text no. 116      
117.Ananth JV, Ban TA, Lehmann HE, Rizvi FA. A survey of phenothiazine induced skin pigmentation. Indian J Psychiatry 1972;14:76-80.  Back to cited text no. 117    Medknow Journal  
118.Pandurangi AK, Ananth 1, Channabavasanna SM. Dyskinesia in an Indian mental hospital. Indian J Psychiatry 1978;20:339-42.  Back to cited text no. 118    Medknow Journal  
119.Kuruvilla K, Kuruvulla A, Kanagasbapthy AS. Serum prolactin levels in schizophrenia: Effects of neuroleptics medication: A preliminary study. Indian J Psychiatry 1986;28:237-47.  Back to cited text no. 119    Medknow Journal  
120.Bhatia MS, Balkrishna, Dhar NK, Khurana SK, Bohra N. Schizophrenia electrolyte profile and the effect of treatment. Indian J Psychiatry 1987;29:275-7.  Back to cited text no. 120    Medknow Journal  
121.Ray D, Samajdar J, Khanna R. Drug induced akathisia: Preliminary report. Indian J Psychiatry 1992;34:159-61.  Back to cited text no. 121    Medknow Journal  
122.Datta S, Subhalakshmi TP, Jeyaseelan L, Kuruvilla K. Risk factors for tardive dyskinesia. Indian J Psychiatry 1994;36:22-4.  Back to cited text no. 122    Medknow Journal  
123.Suresh Kumar PN, Manoj Kumar T. A comparative study of neuroleptic induced neurological side effects in schizophrenia and mood disorder. Indian J Psychiatry 1997;39:110-4.  Back to cited text no. 123      
124.Chopra MP, Prakash SS, Raguram R. The neuroleptic malignant syndrome: An indian experience. Comprehensive Psychiatry 1999;40,19-23.  Back to cited text no. 124      
125.Basu D, Mattoo SK, Khurana H, Malhotra S, Kulhara P. Risperidone- truly non-cataleptogenic ? Hong Kong J Psychiatry 2000;10:2-5.  Back to cited text no. 125      
126.Chopra MP, Raguram R. Recovery and rechallenge after the neuroleptic malignant syndrome. Indian J Psychiatry 2001;43:41-5.  Back to cited text no. 126    Medknow Journal  
127.Gupta V, Magon R, Mishra BP, Sidhu GB, Mahajan R. Risk factors in neuroleptic malignant syndrome. Indian J Psychiatry 2003;45:30-5.  Back to cited text no. 127    Medknow Journal  
128.Nagaraj AKM, Haque Nizamie S, Akhtar S, Sinha BNP, Goyal S. A comparative study of sexual dysfunction due to typical and atypical antipsychotics in remitted bipolar-I disorder. Indian J Psychiatry 2004;46:261-7.  Back to cited text no. 128    Medknow Journal  
129.Guha P, Roy K, Sanyal D, Dasgupta T, Bhattacharya K. Olanzapine-induced obesity and diabetes in Indian patients: A prospective trial comparing olanzapine with typical antipsychotics. J Indian Med Assoc 2005;103:660-4.  Back to cited text no. 129      
130.Jain S, Bhargava M, Gautam S. Weight gain with olanzapine: Drug, gender or age? Indian J Psychiatry 2006;48:39-42.  Back to cited text no. 130  [PUBMED]  Medknow Journal  
131.Sahoo S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: A randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007;68:1793-8.  Back to cited text no. 131      
132.Sahoo S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: A six-week prospective study in Indian female patients. Schizophr Res 2007;95:247.  Back to cited text no. 132      
133.Sahoo S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 2008;28:27-31.  Back to cited text no. 133      
134.Sarkar P, Natarajan C, Gode N. Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients. Indian J Psychiatry 2009;51:208-11.  Back to cited text no. 134      
135.Nagaraj AKM, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. Indian J Psychiatry 2009;51:265-71.  Back to cited text no. 135  [PUBMED]  Medknow Journal  
136.Pandey RS, Sreenivas KN, Subbakrishna DK. Neuroleptic - induced acute dystonia in schizophrenia and mania. Indian J Psychiatry 1992;34:331-3.  Back to cited text no. 136    Medknow Journal  

Top
Correspondence Address:
Ajit Avasthi
Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5545.69261

Rights and Permissions



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8], [Table 9]



 

Top